We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New COVID-19 Test That Identifies T-Cell Signature Better at Detecting Past Coronavirus Infection

By LabMedica International staff writers
Posted on 12 Nov 2020
Illustration
Illustration
New research shows that the unique properties of T cells could make a test that detects virus-specific T cells in a more effective way to assess SARS-CoV-2 exposure before antibodies arise and after they wane.

Using a set of identified “shared” T-cell receptors (TCRs) that are seen across multiple individuals infected with COVID-19, Adaptive Biotechnologies (Seattle, WA, USA) has identified a T-cell signature that can be used for diagnostic purposes. The company is developing a T-cell based diagnostic test that can that detect virus-specific T cells in a more effective way to assess SARS-CoV-2 exposure before antibodies arise and after they wane.

Adaptive recently conducted a head-to-head study in a real-world setting comparing the company’s T-cell test under development with two leading serology tests in 100 patients, ranging from active infection through convalescence. The tests were set at 99.8% specificity to minimize false positives. In the study, 94% of patients were detected as positive by Adaptive’s T-cell test under development vs. 90% (IgG and IgM) and 87% (IgG only) for the serology tests, respectively.

These results, together with a growing body of evidence indicating T cells can be present in the absence of antibodies, suggest the potential utility of Adaptive’s T-cell based approach to detect immune response to SARS-CoV-2 earlier, and in less severe cases, than tests that detect antibody response. Adaptive is currently working with the FDA to generate and package the data required to submit for Emergency Use Authorization (EUA). The company anticipates that the data it continues to generate will expand the clinical applications for its T-cell based testing approach to potentially include assessing pre-existing immunity based on cross-reactive T cells, post infection immunity, and immunity from a vaccine, which may need to be monitored for possible boosters over time.

Related Links:
Adaptive Biotechnologies

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
New
Repetitive Pipette
VWR® Stepper Pro
New
Multi-Chamber Washer-Disinfector
WD 390

Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
ADLM